Dosing & Uses
Atrial Fibrillation
IV antiarrhythmic pending FDA approval for rapid conversion of recent onset atrial fibrillation to sinus rhythm
Next:
Pharmacology
Mechanism of Action
Acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent fashion
Prominently blocks certain potassium channels, specifically, the atrial-selective potassium current Iκur
It is also a sodium channel blocker, depending upon heart rate (HR); as HR increases, affinity for the sodium channel increases; additionally, as the HR decreases, vernakalant binding to the sodium channel decreases
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
